IDEVAX

medical devices

About

IDEVAX is a medical device company based in Antwerp and Wijnegem, Belgium, specializing in skin drug delivery solutions. Founded in December 2020 by Vanessa Vankerckhoven and Koen Beyers, the company emerged from the University of Antwerp and is ISO13485 certified. IDEVAX focuses on innovative technologies for prophylactic vaccination and therapeutic applications, including immunotherapy and cancer treatment. The company's flagship product, VAX-ID, is a patented intradermal injection device that delivers vaccines and drugs directly into the skin's dermal layer. This method allows for significant dose sparing, requiring only about one-tenth of the dose compared to traditional injection methods, while enhancing immune response effectiveness. VAX-ID is CE marked and is expected to receive FDA approval by the end of 2025. IDEVAX targets customers in the healthcare and pharmaceutical sectors, including vaccine developers and medical institutions, aiming to improve patient comfort and optimize drug efficacy.

Technologies

Outlook Microsoft Office 365 Google Font API Gravity Forms reCAPTCHA Google Tag Manager WordPress.org Mobile Friendly Nginx AI Viewpoint Proofpoint

Keywords

medical devices intradermal injection vaccination vaccines infectious diseases drug delivery medical equipment manufacturing medical device medical equipment and supplies manufacturing immune response enhancement vax-id ease of use iso13485 certified white papers cell therapy clinical research device design investigational device research use only dose-sparing vaccine vaccination device cancer immunotherapy therapeutic drug delivery skin drug delivery device lymphatic imaging lymphatic applications patented drug delivery platform b2b vaccination technology ce class iia device

Location

Antwerp, Flanders, Belgium

Related Companies

Companies in the same industry